Skip to main content

Table 2 Patient treatment patterns among the treatment-naïve propensity score-matched study population (N = 1,746)

From: Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort

Post-index treatment patterns

Total

Febuxostat

Allopurinol

Febuxostat vs. allopurinol

(N = 1,746)

(N = 873)

(N = 873)

P value

 

N

%

n

%

n

%

 

Prophylaxis treatment

940

53.8%

510

58.4%

430

49.3%

<0.001

  Steroids

597

34.2%

323

37.0%

274

31.4%

0.013

  NSAIDs

362

20.7%

180

20.6%

182

20.9%

0.906

  Colchicines

354

20.3%

225

25.8%

129

14.8%

<0.001

Index febuxostat dose

       

  40 mg

726

41.6%

726

83.2%

-

-

-

  80 mg

147

8.4%

147

16.8%

-

-

-

Index allopurinol dose

       

  100 mg

350

20.1%

-

-

350

40.1%

-

  101-299 mg

129

7.4%

-

-

129

14.8%

-

  300 mg

369

21.1%

-

-

369

42.3%

-

  >300 mg

25

1.4%

-

-

25

2.9%

-

Index medication dose change

458

26.2%

160

18.3%

298

34.1%

<0.001

Percent of dose change

       

  51-99% reduction

28

1.6%

0

0.0%

28

3.2%

<0.001

  1-50% reduction

38

2.2%

6

0.7%

32

3.7%

<0.001

  1-50% increase

46

2.6%

1

0.1%

45

5.2%

<0.001

  51-100% increase

241

13.8%

143

16.4%

98

11.2%

0.002

  >100% increase

105

6.0%

10

1.2%

95

10.9%

<0.001

 

Mean

SD

Mean

SD

Mean

SD

 

Time to dose change (days)

198

197

211

188

192

202

0.32

Index medication dose immediately prior to sUA goal attainment of <6 mg/dl

N/A

N/A

54.1

20.5

275.8

109.5

N/A

Index medication dose immediately prior to sUA goal attainment of <5 mg/dl

N/A

N/A

55.0

21.5

302.0

125.8

N/A

  1. N/A, not applicable, since the dose for febuxostat and allopurinol are different and averaging of doses is meaningless. NSAIDs, nonsteroidal anti-inflammatory drugs; SD, standard deviation; sUA, serum urate.